


PATENTS

CERTIFICATE OF EXPRESS MAIL

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail in an envelope addressed to: Mail Stop Patent Application Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on July 29, 2003.

PLEASE CHARGE ANY DEFICIENCIES UP TO \$300 OR CREDIT ANY EXCESS WITH THIS DOCUMENT TO OUR DEPOSIT ACCOUNT No. 14-1263


Jennifer Conrlington

Express Mail Label EV 328769057 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No.	:	to be assigned	Confirmation No.	to be assigned
Applicant	:	Kirk E. Vandezande		
Filed	:	Currently herewith		
TC/A.U.	:	to be assigned		
Examiner	:	to be assigned		
Docket No.	:	101384-22		
Customer No.	:	27388		

Mail Stop Patent Application
Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISLCOSURE STATEMENT

Sir:

Transmitted herewith is an Information Disclosure Statement in the above-identified application. This Statement is submitted:

- ☒ [X] within three months of the application filing date;
☐ [] more than three months from the application filing date but before the mailing date of the first Office Action on the merits.

It is respectfully requested that these references be (1) fully considered by the Patent and Trademark Office during the examination of this application; and (2) printed on any patent which may issue on this application. Applicants request that a copy of Form PTO-1449, as considered and initialed by the Examiner, be returned with the next communication.

In accordance with 37 C.F.R. §1.98, submission of this statement requires no fee. However, if for any reason a fee is due, the Commissioner is hereby authorized to charge payment of any fees required in connection with this Information Disclosure Statement to Deposit Account No. 14-1263. A duplicate copy of this letter is transmitted herewith.

An early and favorable action is respectfully submitted.

Respectfully Submitted,



Christa Hildebrand

Reg. No. 34,953

Norris, McLaughlin & Marcus P.A.

220 East 42nd Street - 30th Floor

New York, N.Y. 10017

Telephone: (212)808-0700

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	1
-------	---	----	---

Complete if Known

Application Number	60/398,780
Filing Date	July 29,2003
First Named Inventor	Kirk E. Vandezande
Art Unit	
Examiner Name	
Attorney Docket Number	101384-22

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ⁴ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	60/398,780
				Filing Date	July 29, 2003
				First Named Inventor	Kirk E. Vandezande
				Art Unit	
				Examiner Name	
Sheet	1	of	3	Attorney Docket Number	101384-22

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	B1	ANTONARAKIS, Stylianos E. and the Nomenclature Working Group (1998). Recommendations for a nomenclature system for human gene mutations. Human Mutation 11(1):1-3. Hoboken, NJ: Wiley-Liss, Inc.	
	B2	BENEDICT WF, Murphree AL, Banerjee A, Spina CA, Sparkes MC, Sparkes RS. Patient with 13 chromosome deletion: evidence that the retinoblastoma gene is a recessive cancer gene. Science 219(4587):973-5 (Feb 25, 1983).	
	B3	BLANQUET V, Turleau C, Gross-Morand MS, S�narnaud-Beaufort C, Doz F, Besmond C. Spectrum of germline mutations in the RB1 gene: a study of 232 patients with hereditary and non hereditary retinoblastoma. Hum.Mol.Genet. 4:383-388 (1995).	
	B4	CARTER MS, Daskow J, Morris P, Li S, Nhim RP, Sandstedt S, Wilkinson MF. A regulatory mechanism that detects premature nonsense codons in T-cell receptor transcripts in vivo is reversed by protein synthesis inhibitors in vitro. J Biol Chem 270:28995-9003 (1995).	
	B5	CYSTIC FIBROSIS GENOTYPE-PHENOTYPE CONSORTIUM. Correlation between Genotype and Phenotype in Patients with Cystic Fibrosis. N Eng J Med 329(18):1308-1313 (1993).	
	B6	DEN DUNNEN JT, Antonarakis E. Nomenclature for the description of human sequence variations Hum Genet 109:121-124 (2001).	
	B7	DEN DUNNEN JT, Grootsholten PM, Bakker E, Blonden LA, Ginjaar HB, Wapenaar MC, van Paassen HM, van Broeckhoven C, Pearson PL, van Ommen GJ. Topography of the Duchenne muscular dystrophy (DMD) gene: FIGE and cDNA analysis of 194 cases reveals 115 deletions and 13 duplications. Am J Hum Genet 45(6):835-47 (Dec 1989).	
	B8	DICOMMO D, Gallie BL, Bremner R. Retinoblastoma: the disease, gene and protein provide critical leads to understand cancer. Semin Cancer Biol 10:255-69 (2000).	
	B9	DUNN JM, Phillips RA, Zhu X, Becker AJ, Gallie BL. Mutations in the RB1 gene and their effects on transcription. Mol. Cell. Biol. 9:4594-4602 (1989).	
	B10	GAD S, Aurias A, Puget N, Mairal A, Schurra C, Montagna M, Pages S, Caux V, Mazoyer S, Bensimon A, Stoppa-Lyonnet D (2001) Color bar coding the BRCA1 gene on combed DNA: a useful strategy for detecting large gene rearrangements. Genes Chromosomes Cancer 31(1):75-84 (May 2001).	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	60/398,780
				Filing Date	July 29, 2003
				First Named Inventor	Kirk E. Vandezande
				Art Unit	
				Examiner Name	
Sheet	2	of	3	Attorney Docket Number	101384-22

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	B11	HEGDE MR, Chong B, Fawcner MJ, Leary J, Shelling AN, Culling B, Winship I, Love DR. Hierarchical mutation screening protocol for the BRCA1 gene. Human Mutation 16(5):422-30 (Nov 2000).	
	B12	HENTZE MW, Kulozik AE. A perfect message: RNA surveillance and nonsense-mediated decay. Cell 96:307-10 (1999).	
	B13	JANSON M, Nordenskjoeld M. A constitutional mutation within the retinoblastoma gene detected by PFGE. Clin Genet 45:5-10 (1994).	
	B14	KLUTZ M, Brockmann D, Lohmann DR. A Parent-of-Origin Effect in Two Families with Retinoblastoma is Associated with a Distinct Splice Mutation in the RB1 Gene. Am J Hum Genet 71:174-9 (2002).	
	B15	LEE JO, Russo AA, Pavletich NP. Structure of the retinoblastoma tumour-suppressor pocket domain bound to a peptide from HPV E7. Nature 391(6670):859-65 (1998).	
	B16	LOHMANN DR, Horsthemke B, Gillessen KG, Stefani FH, Hoffer H. Detection of small RB1 gene deletions in retinoblastoma by multiplex PCR and high-resolution gel electrophoresis. Hum Genet 89:49-53 (1992).	
	B17	LOHMANN DR, Brandt B, Höpping W, Passarge E, Horsthemke B. Distinct RB1 gene mutations with low penetrance in hereditary retinoblastoma. Hum.Genet. 94:349-354 (1994).	
	B18	LOHMANN DR. RB1 gene mutations in retinoblastoma. Hum Mutat 14:283-288 (1999).	
	B19	MCFALL RC, Sery TW, Makadon M. Characterization of a new continuous cell line derived from a human retinoblastoma. Cancer Res 37:1003-1010 (1977).	
	B20	NOORANI HZ, Khan HN, Gallie BL, Detsky AS. Cost comparison of molecular versus conventional screening of relatives at risk for retinoblastoma. Am J Hum Genet 59:301-7 (1996).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	60/398,780
Filing Date	July 29, 2003
First Named Inventor	Kirk E. Vandezande
Art Unit	
Examiner Name	
Attorney Docket Number	101384-22

Sheet 3 of 3

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	B21	OTTERSON GA, Chen W, Coxon AB, Khleif SN, Kaye FJ. Incomplete penetrance of familial retinoblastoma linked to germ-line mutations that result in partial loss of RB function. Proc Natl Acad Sci USA 94:12036-40 (1997).	
	B22	SCHMUTTE C, Jones PA. Involvement of DNA methylation in human carcinogenesis. Biol Chem 379:377-88 (1998).	
	B23	SIPPEL KC, Fraioli RE, Smith GD, Schalkoff ME, Sutherland J, Gallie BL, Dryja TP. Frequency of somatic and germ-line mosaicism in retinoblastoma: implications for genetic counseling. Am J Hum Genet 62:610-9 (1998).	
	B24	WHITAKER LL, Su H, Baskaran R, Knudsen ES, Wang JY. Growth suppression by an E2F-binding-defective retinoblastoma protein (RB): contribution from the RB C pocket. Mol Cell Biol 18:4032-42 (1998).	
	B25	ZESCHNIGK M, Lohmann DR, Horsthemke B. A PCR test for the detection of hypermethylated alleles at the retinoblastoma locus [letter]. J Med Genet 36:793-4 (1999).	
	26	VANDEZANDE, K. Hierarchical Optimization for Procedural Effectiveness; Improves Health Care for Families with Retinoblastoma. Copy of Poster presented at the American Society of Human Genetics conference (10/2001).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.